Puma Biotechnology | PBYI - Loan Capital


Puma Biotechnology reported $10.87M in Loan Capital for its fiscal quarter ending in June of 2025.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Esperion Therapeutics USD 262.48M 235.95M Jun/2024
Gilead Sciences USD 22.14B 5M Sep/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
MacroGenics USD 70.26M 4K Sep/2025
Moderna USD 26M 6M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Takeda JPY 4.27T 81.29B Dec/2025
TG Therapeutics USD 245.34M 303K Sep/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025